Condition 1: Dyspepsia. Condition 2: Helicobacter pylori infection. Dyspepsia Disease of stomach and duodenum, unspecified
Conditions
Interventions
Intervention 1: control group : 4 capsules containing pharmaceutical starch daily for 8 weeks. Intervention 2: intervention group 1 : 4 capsules of 500 mg containing nigella sativa powder daily for 8
Placebo
Treatment - Other
control group : 4 capsules containing pharmaceutical starch daily for 8 weeks
intervention group 1 : 4 capsules of 500 mg containing nigella sativa powder daily for 8 weeks
intervention group 2 : 4 capsules of 500 mg containing cuminum cyminum powder daily for 8 weeks
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: People who have any of the following conditions can participate in the study: 1. Having positive result of helicobacter pylori infection and dyspepsia symptoms 2. Having positive result of helicobacter pylori infection and dyspepsia symptoms with mild to moderate peptic ulcer 3. Having positive result of helicobacter pylori infection and dyspepsia symptoms with mild to moderate gastritis Exclusion criteria: 1. Having a history of gastric cancer or gastric surgery 2. Active GI bleeding and intense gastritis 3. Having an inflammatory or chronic disease (kidney disease, liver disease, inflammatory bowel disease, heart ischemia, diabetes, lung disease, asthma, cancer, HIV, systemic inflammation and…) 4. Taking any antibiotics or bismuth from 6 weeks before the study 5. Taking all types of medication for helicobacter pylori before the study 6. Pregnancy or lactation at the same time as studying 7. Drinking alcohol or using narcotic at the same time as studying 8. Eating a specific diet (vegetarian diet and …) at the same time as studying 9. Body mass index greater than 30 10. Exiting patient during the study 11. Any changes in the use of anti-inflammatory drugs and corticosteroids at the same time as studying 12. Any changes in the use of supplements such as omega 3, selenium, zinc, beta carotene, vitamin E, C and… at the same time as studying 13. Unwillingness to continue the study
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HsCRP. Timepoint: at the beginning and the end of the study ( after 8 weeks ). Method of measurement: hsCRP kit. | — |
Secondary
| Measure | Time frame |
|---|---|
| Eradication percentage of helicobacter pylori. Timepoint: at the end of the study. Method of measurement: stool antigen test of helicobacter pylori.;Malondialdehyde. Timepoint: at the beginning and the end of the study. Method of measurement: malondialdehyde kit.;Interleukin 8. Timepoint: at the beginning and the end of the study. Method of measurement: interleukin 8 kit.;Quality of life. Timepoint: at the beginning and the end of the study. Method of measurement: sf-36 questionnaire.;Dyspepsia symptoms. Timepoint: at the beginning and the end of the study. Method of measurement: ROMEIII questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHedie Yousefnejad
Shiraz University of Medical Sciences, Faculty of Nutrition and Food Sciences
Outcome results
None listed